Armata Pharmaceuticals
ARMP
17 hedge funds and large institutions have $479K invested in Armata Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.
55% more funds holding
Funds holding: 11 → 17 (+6)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
38% less capital invested
Capital invested by funds: $772K → $479K (-$293K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$39.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.3K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$15.7K |
| 5 |
SXL
Summit X LLC
Chesterfield,
Missouri
|
+$11.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$532K |
| 2 |
Renaissance Technologies
New York
|
-$15.1K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$820 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $136K | -$532K | -41,583 | -80% |
|
|
2
Renaissance Technologies
New York
| $102K | -$15.1K | -1,179 | -13% |
|
|
ARTA
3
A.R.T. Advisors
New York
| $53K | +$15.7K | +1,223 | +41% |
|
|
VF
4
Virtu Financial
New York
| $40K | +$39.9K | +3,116 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $34K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $27K | +$26.9K | +2,100 | New |
|
|
TSS
7
Two Sigma Securities
New York
| $18K | +$18.3K | +1,430 | New |
|
8
UBS Group
Zurich,
Switzerland
| $17K | +$4.41K | +344 | +36% |
|
|
MP
9
MSD Partners
New York
| $14K | – | – | – |
|
|
SF
10
Synovus Financial
Columbus,
Georgia
| $14K | – | – | – |
|
|
SXL
11
Summit X LLC
Chesterfield,
Missouri
| $12K | +$11.9K | +929 | New |
|
12
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $7K | +$7.31K | +571 | New |
|
|
PAM
13
Panagora Asset Management
Boston,
Massachusetts
| $4K | -$820 | -64 | -18% |
|
14
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
15
Citigroup
New York
| – | +$13 | +1 | New |
|
ARMP Hedge Fund Activity: Q3 2017 in Review
17 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q3 2017, worth a combined $479K — down 38% from $772K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARMP positions and 0 closed out — a net gain of 6 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $39.9K. The largest seller was Sabby Management, cutting an estimated $532K.
- 17 institutional investors held Armata Pharmaceuticals (ARMP) as of Q3 2017, up from 11 in Q2 2017.
- Funds reported $479K of Armata Pharmaceuticals stock for Q3 2017, down 38% quarter-over-quarter.
- 6 funds opened new Armata Pharmaceuticals positions in Q3 2017 and 0 closed out, a net change of +6 holders.
- The largest Armata Pharmaceuticals buyer in Q3 2017 was Virtu Financial, an estimated $39.9K added.
- The largest Armata Pharmaceuticals seller in Q3 2017 was Sabby Management, an estimated $532K sold.
Based on aggregated 13F filings for Q3 2017.